Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2750
Single User License Price INR 189750
Corporate User License Price USD 4500
Corporate User License Price INR 310500
Site License Price USD 3500
Site License Price INR 241500
Request a Quote

Report Title

Global Conjunctivitis Drugs Market 2018-2024

Quote Request for License Type
License Type Price  
Single User License USD 2750
Site License USD 3500
Enterprise Wide License USD 4500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Global Conjunctivitis Drugs Market 2018-2024


Quote Request for License Type
License Type Price  
Single User License USD 2750
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Global Conjunctivitis Drugs Market 2018-2024

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Global Conjunctivitis Drugs Market 2018-2024



Executive Summary

Global Bacterial Conjunctivitis Drugs Market-Drivers, Restraints, Opportunities, Trends, and Forecast: 2018-2024

Overview: Bacterial conjunctivitis is a contagious eye infection in which the conjunctiva of one or both the eyes are infected by bacteria such as Staphylococci, Gonococci, Chlamydia, and Streptococci. The infection caused by Chlamydia trachomatis and Neisseria gonorrhea species are extremely severe. However, there are many antibiotics that help in curing these conditions, thus ensuring quicker clearance of the indications of infection. Healio reported that nearly 5 million bacterial conjunctivitis cases are registered every year. There are many antibiotics currently used for the treatment, which include Besivance, Zymaxid, Maxitrol, and AzaSite. These antibiotics can be administered via oral, transdermal, and otic.

Although, most of the bacterial conjunctivitis

are self-limiting, yet topical antibiotics are suggested to cut the duration of the disease and avoid the spreading of infection. A wide range of antibiotics are generally used as a primary treatment option for bacterial conjunctivitis. Topical antibiotics are suggested to deliver the highest dose of the drug straight to the infection site, more than what is usually achieved by oral and other routes. Consequently, the broad spectrum of antibiotic of a single drug is improved.

Market Analysis: The Global Bacterial Conjunctivitis Drugs Market is estimated to witness a CAGR of 2.1% during the forecast period 2018-2024. The bacterial conjunctivitis drugs market is analyzed based on two segments-drug class and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America accounts for the largest share of the bacterial conjunctivitis market, followed by Europe, Asia Pacific, and Rest of the World. More than 40% of the market is occupied by North America, with the US being the major contributor to the market growth.

Drug Class Analysis: Based on drug classes, the market is segmented into fluoroquinolones, aminoglycosides, macrolides, and others. Fluoroquinolones have a dominant market share for bacterial conjunctivitis. However, this drug class is likely to reduce its market share by 7.2% by the end of 2024 due to weak research pipeline. The highest growth rate is witnessed by aminoglycosides, followed by macrolides. However, the loss of patent of blockbuster drugs, such as Moxeza, Besivance, Vigamox, and Zymaxid, has hampered the growth of the market.

Key Players: The major players in the market include Novartis, Valeant Pharmaceuticals International, Teva Pharmaceuticals, and Akron Inc. Perrigo Corporation, Bayer AG, Pfizer, Daiichi Sankyo Inc., Merck & Co., and F. Hoffmann-La Roche are few of the prominent drugs manufacturers in the market.

Competitive Analysis: Many blockbuster drugs are likely to lose their patents in the market, which in turn, has increased the advent of generic drugs with similar efficacy and less cost. Novartis AG is one of the global leaders in the bacterial conjunctivitis market. Vigamox and Moxeza are the key products of the company, which are expected to lose their patents by 2020. This patent expiry is expected to show a negative impact on the company revenue and its market position. Other strategies used by the market players are acquisitions. For instance, in 2015, Shire Plc acquired Foresight Biotherapeutics for a value of USD 300 million. This acquisition added experimental eye drop FST-100 into the Shire Plc's portfolio to treat both viral and bacterial conjunctivitis.

Benefits: The report provides complete details about the usage and adoption rate of bacterial conjunctivitis drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player's initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:

 

Table of Contents

1 Industry Outlook 8

1.1 Industry Overview 8

1.1.1 Global Driver for Pharmaceutical Demand: 9

1.1.2 Pharmaceutical spending region wise 9

1.1.3 R&D pipeline in pharmaceutical industry 9

1.1.4 Top pharma drugs by sales in 2017 (USD Million) 11

1.2 Industry Trends 12

1.3 Total Addressable Market 13

2 Report Outline 15

2.1 Report Scope 15

2.2 Report Summary 15

2.3 Research Methodology 16

2.4 Report Assumptions 16

3 Market Snapshot 18

3.1 Market Definition-Infoholic Research 18

3.2 Segmented Addressable Market (SAM) 18

3.3 Trends of Bacterial Conjunctivitis Drugs Market 19

3.4 Related Markets 20

3.4.1 Contact lenses 20

3.4.1.1 Trends of Contact Lens Market 21

3.4.2 Oncology (Cancer) Drugs 21

3.4.3 Active pharmaceutical ingredients (APIs) 22

3.4.4 Over the counter drugs (OTC) 22

4 Market Outline 23

4.1 Market Segmentation 23

4.2 Porter 5(Five) Forces 24

4.3 PEST Analysis 25

5 Market Characteristics 26

5.1 Market Dynamics of Bacterial Conjunctivitis Drugs Market 26

5.1.1 Drivers 27

5.1.1.1 Increasing awareness among patient population about pink eye disease 27

5.1.1.2 Rising prevalence of bacterial conjunctivitis 27

5.1.2 Opportunities 27

5.1.2.1 Increasing clinical trials 27

5.1.3 Restraints 28

5.1.3.1 Expiry of patents for blockbuster drugs 28

5.1.3.2 Complex drug development process 28

5.1.4 DRO-Impact Analysis 29

5.1.5 Key Stakeholders 29

6 Application: Market Size and Analysis 31

6.1 Overview 31

6.2 Fluoroquinolones 32

6.3 Aminoglycosides 33

6.4 Macrolides 34

6.5 Others 35

7 Regions: Market Size and Analysis 37

7.1 Overview 37

7.2 North America 38

7.2.1 Overview 38

7.3 Europe 39

7.3.1 Overview 39

7.4 APAC 41

7.4.1 Overview 41

7.5 Rest of the World 42

7.5.1 Overview 42

8 Competitive Landscape 44

9 Vendor Profiles 46

9.1 Novartis AG 46

9.1.1 Overview 46

9.1.2 Business Unit 51

9.1.3 Geographic Presence 51

9.1.4 Business Focus 52

9.1.5 SWOT Analysis 52

9.1.6 Business Strategy 53

9.2 Valeant Pharmaceuticals International Inc. 54

9.2.1 Overview 54

9.2.2 Business Unit 56

9.2.3 Geographic Presence 57

9.2.4 Business Focus 57

9.2.5 SWOT Analysis 58

9.2.6 Business Strategy 58

9.3 Teva Pharmaceutical Industries Ltd. 59

9.3.1 Overview 59

9.3.2 Business Unit 61

9.3.3 Geographic Presence 62

9.3.4 Business focus 63

9.3.5 SWOT analysis 63

9.3.6 Business Strategy 64

9.4 Akron Inc 64

9.4.1 Overview 64

9.4.2 Business Focus 67

9.4.3 SWOT Analysis 67

9.4.4 Business Strategy 68

10 Companies to Watch For 69

10.1 Santen Pharmaceutical Co., Ltd. 69

10.1.1 Overview 69

10.2 Perrigo Company plc 70

10.2.1 Overview 70

10.3 Merck & Co. 71

10.3.1 Overview 71

10.4 Pfizer Inc., 72

10.4.1 Overview 72

10.4.2 Highlights 74

10.5 Daiichi Sankyo, Inc. 74

10.5.1 Overview 74

10.5.2 Overview 75

10.6 Bayer AG 75

10.6.1 Overview 75

10.7 F. Hoffmann-La Roche 76

10.7.1 Overview 76

Annexure 80

Abbreviations 80

 

 

 

 

 

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

Charts

 

CHART 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010-2016) 9

CHART 2 R&D INVESTMENT BY TOP 10 COMPANIES (USD BN) 10

CHART 3 PHARMACEUTICAL DRUGS BY SALES, 2017 12

CHART 4 CAUSES OF SIGHT LOSS GLOBALLY 13

CHART 5 RESEARCH METHODOLOGY OF GLOBAL BACTERIAL CONJUNCTIVITIS DRUGS MARKET 16

CHART 6 GLOBAL BACTERIAL CONJUCTIVITIS DRUGS MARKET REVENUE, 2017-2024 (USD MILLION) 19

CHART 7 OVERVIEW OF GLOBAL CONTACT LENSES USER STATISTICS 20

CHART 8 SEGMENTATION OF GLOBAL BACTERIAL CONJUNCTIVITIS DRUGS MARKET 23

CHART 9 PORTER 5 FORCES OF BACTERIAL CONJUNCTIVITIS DRUGS MARKET 24

CHART 10 PEST ANALYSIS OF BACTERIAL CONJUNCTIVITIS DRUGS MARKET 25

CHART 11 MARKET DYNAMICS-DRO ANALYSIS 26

CHART 12 DRO-IMPACT ANALYSIS OF GLOBAL BACTERIAL CONJUCTIVITIS DRUGS MARKET 29

CHART 13 KEY STAKEHOLDERS 29

CHART 14 BACTERIAL CONJUNCTIVITES DRUGS MARKET BY APPLICATION SEGMENTATION, 2017 VS 2024 (%) 31

CHART 15 FLUOROQUINOLONES DRUGS MARKET REVENUE, 2017-2024 (USD MILLION) 33

CHART 16 AMINOGLYCOSIDES DRUGS MARKET REVENUE, 2017-2024 (USD MILLION) 34

CHART 17 MACROLIDES DRUGS MARKET REVENUE, 2017-2024 (USD MILLION) 34

CHART 18 OTHER BACTERIAL CONJUNCTIVITIS DRUGS MARKET REVENUE, 2017-2024 (USD MILLION) 35

CHART 19 BACTERIAL CONJUCNTIVITIS DRUGS MARKET BY REGIONAL SEGMENTATION, 2017 VS 2024 (%) 37

CHART 20 BACTERIAL CONJUNCTIVITIS DRUGS MARKET REVENUE IN NORTH AMERICA, 2017-2024 (USD MILLION) 38

CHART 21 BACTERIAL CONJUNCTIVITIS DRUGS MARKET REVENUE IN THE EUROPE REGION, 2017-2023 (USD MILLION) 40

CHART 22 BACTERIAL CONJUNCTIVITIS DRUGS MARKET REVENUE IN THE APAC REGION, 2017-2024 (USD MILLION) 41

CHART 23 BACTERIAL CONJUNCTIVITIS DRUGS MARKET REVENUE IN REST OF THE WORLD, 2017-2024 (USD MILLION) 42

CHART 24 NOVARTIS AG: OVERVIEW SNAPSHOT 46

CHART 25 NOVARTIS AG: BUSINESS UNITS 51

CHART 26 NOVARTIS AG: GEOGRAPHICAL PRESENCE 51

CHART 27 NOVARTIS AG: SWOT ANALYSIS 52

CHART 28 VALEANT PHARMACEUTICALS INTERNATIONAL INC: OVERVIEW SNAPSHOT 55

CHART 29 VALEANT PHARMACEUTICALS INTERNATIONAL INC: BUSINESS UNITS 56

CHART 30 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: GEOGRAPHICAL PRESENCE 57

CHART 31 VALEANT PHARMACEUTICALS INTERNATIONAL INC: SWOT ANALYSIS 58

CHART 32 TEVA PHARMACEUTICAL INDUSTRIES LTD: OVERVIEW SNAPSHOT 60

CHART 33 TEVA PHARMACEUTICAL INDUSTRIES LTD: BUSINESS UNITS 61

CHART 34 TEVA PHARMACEUTICAL INDUSTRIES LTD: GEOGRAPHICAL PRESENCE 62

CHART 35 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS 63

CHART 36 AKRON INC: OVERVIEW SNAPSHOT 65

CHART 37 AKRON INC.: BUSINESS UNITS 67

CHART 38 AKRON INC.: SWOT ANALYSIS 67

 

Tables

 

TABLE 1 PATENT EXPIRATION OF RESPIRATORY DRUGS 28

TABLE 2 BACTERIAL CONJUNCTIVITES DRUGS MARKET REVENUE BY DRUG CLASS, 2017-2024 (USD MILLION) 32

TABLE 3 BACTERIAL CONJUNCTIVITIS DRUGS MARKET REVENUE BY REGIONS, 2017-2024 (USD MILLION) 37

TABLE 4 POPULATION LIVING IN ENDEMIC AREAS OF TRACHOMA BY COUNTRY 42

TABLE 5 NOVARTIS AG: OFFERINGS 46

TABLE 6 NOVARTIS AG: RECENT DEVELOPMENTS 47

TABLE 7 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: OFFERINGS 54

TABLE 8 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: RECENT DEVELOPMENTS 54

TABLE 9 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERINGS 59

TABLE 10 TEVA PHARMACEUTICAL INDUSTRIES LTD: RECENT DEVELOPMENTS 59

TABLE 11 AKORN INC: OFFERINGS 64

TABLE 12 AKRON INC.: RECENT DEVELOPMENTS 65

TABLE 13 SANTEN PHARMACEUTICAL CO., LTD.: OVERVIEW 69

TABLE 14 SANTEN PHARMACEUTICAL CO., LTD.: RECENT DEVELOPMENTS 69

TABLE 15 PERRIGO COMPANY PLC: OVERVIEW 70

TABLE 16 PERRIGO COMPANY PLC: RECENT DEVELOPMENTS 70

TABLE 17 MERCK & CO: OVERVIEW 71

TABLE 18 MERCK & CO: RECENT DEVELOPMENTS 71

TABLE 19 PFIZER: RECENT DEVELOPMENTS 73

TABLE 20 DAIICHI SANKYO, INC.: RECENT DEVELOPMENTS 74

TABLE 21 BAYER AG: OVERVIEW 75

TABLE 22 BAYER AG: RECENT DEVELOPMENTS 75

TABLE 23 F. HOFFMANN-LA ROCHE: OVERVIEW 76

TABLE 24 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS 76

 

 

Novartis, Valeant Pharmaceuticals International, Teva Pharmaceuticals, and Akron Inc. Perrigo Corporation, Bayer AG, Pfizer, Daiichi Sankyo Inc., Merck & Co., and F. Hoffmann-La Roche


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person